Pre-order Enquiry
Request Free Sample
Global CAR T-cell Therapy Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
SKU ID : Maia-16576049 | Publishing Date : 20-Oct-2020 | No. of pages : 111
Request Sample
Request Customization
Check Discounts
CAR T cell therapy refers to the type of cancer treated by injecting T cells engineered with chimeric antigen receptor (CAR) proteins. It involves infusion of engineered T cells to attack tumors or to cause cancer cells. Basically, in this therapy, T cells are collected and redesigned and reinfused into the patient with CAR protein in the laboratory. These T cells now act as attackers of tumor-causing cells.
Based on the CAR T-cell Therapy market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.
In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.
Key players in the global CAR T-cell Therapy market covered in Chapter 5:
Juno Therapeutics
Legend Biotech
Novartis International AGech
Pfizer, Inc.
Mustang Bio, Inc.
Sorrento Therapeutics Inc.
CARsgen Therapeutics, Ltd.
Pfizer, Inc.
Aurora Biopharma Inc.
Bluebird Bio, Inc.
CARsgen Therapeutics, Ltd.
Kite Pharma, Inc.
In Chapter 6, on the basis of types, the CAR T-cell Therapy market from 2015 to 2025 is primarily split into:
CD 19
CD 20
CD22
CD30
CD33
HER1
HER2
Meso
Egfrvlll
In Chapter 7, on the basis of applications, the CAR T-cell Therapy market from 2015 to 2025 covers:
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non Hodgkin Leukemia
Multiple Myeloma
Pancreatic Cancer
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa
2019
Based on the CAR T-cell Therapy market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.
In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.
Key players in the global CAR T-cell Therapy market covered in Chapter 5:
Juno Therapeutics
Legend Biotech
Novartis International AGech
Pfizer, Inc.
Mustang Bio, Inc.
Sorrento Therapeutics Inc.
CARsgen Therapeutics, Ltd.
Pfizer, Inc.
Aurora Biopharma Inc.
Bluebird Bio, Inc.
CARsgen Therapeutics, Ltd.
Kite Pharma, Inc.
In Chapter 6, on the basis of types, the CAR T-cell Therapy market from 2015 to 2025 is primarily split into:
CD 19
CD 20
CD22
CD30
CD33
HER1
HER2
Meso
Egfrvlll
In Chapter 7, on the basis of applications, the CAR T-cell Therapy market from 2015 to 2025 covers:
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non Hodgkin Leukemia
Multiple Myeloma
Pancreatic Cancer
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
